Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy

Neurobiology of Aging

Volumn 35, Issue 9, 2014, Pages 2091-2095

  Bomben, Valerie ^a   Holth, Jerrah ^a   Reed, John ^a   Cramer, Paige ^b   Landreth, Gary ^b   Noebels, Jeffrey ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Bexarotene; Epilepsy; Hyperexcitability

Indexed keywords

BEXAROTENE; POTASSIUM CHANNEL KV1.1; AMYLOID BETA PROTEIN; RETINOID X RECEPTOR; TETRALIN DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; EPILEPSY; GENETIC MODEL; HIPPOCAMPUS; KNOCKOUT MOUSE; MEMORY CONSOLIDATION; MOUSE; MOUSE MODEL; NERVE CELL EXCITABILITY; NERVE CELL NETWORK; NONHUMAN; PRIORITY JOURNAL; SEIZURE; TREATMENT DURATION; AGONISTS; ANIMAL; BRAIN CORTEX; COGNITION; DRUG EFFECTS; MEMORY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PSYCHOLOGY;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CEREBRAL CORTEX; COGNITION; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; HIPPOCAMPUS; MEMORY; MICE; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES;

EID: 84902084909     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.03.029     Document Type: Article

References (22)

1. Bachmeier C., Beaulieu-Abdelahad D., Crawford F., Mullan M., Paris D. Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier. J.Mol. Neurosci. 2013, 49:270-276.
2. Blanchard B.J., Thomas V.L., Ingram V.M. Mechanism of membrane depolarization caused by the Alzheimer Abeta1-42 peptide. Biochem. Biophys. Res. Commun. 2002, 293:1197-1203.
3. Boehm M.F., Zhang L., Zhi L., McClurg M.R., Berger E., Wagoner M., Mais D.E., Suto C.M., Davies J.A., Heyman R.A., Nadzan A.M. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J.Med. Chem. 1995, 38:3146-3155.
4. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.Y., Karlo J.C., Zinn A.E., Casali B.T., Restivo J.L., Goebel W.D., James M.J., Brunden K.R., Wilson D.A., Landreth G.E. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
5. Fitz N.F., Cronican A.A., Lefterov I., Koldamova R. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340:924.c.
6. Glasscock E., Yoo J.W., Chen T.T., Klassen T.L., Noebels J.L. Kv1.1 potassium channel deficiency reveals brain-driven cardiac dysfunction as a candidate mechanism for sudden unexplained death in epilepsy. J.Neurosci. 2010, 30:5167-5175.
7. Holth J.K., Bomben V.C., Reed J.G., Inoue T., Younkin L., Younkin S.G., Pautler R.G., Botas J., Noebels J.L. Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J.Neurosci. 2013, 33:1651-1659.
8. Howell S.R., Shirley M.A., Grese T.A., Neel D.A., Wells K.E., Ulm E.H. Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and invitro activity at retinoid receptors. Drug Metab. Dispos. 2001, 29:990-998.
9. Hurst R.E. Bexarotene ligand pharmaceuticals. Curr. Opin. Investig. Drugs 2000, 1:514-523.
10. Laclair K.D., Manaye K.F., Lee D.L., Allard J.S., Savonenko A.V., Troncoso J.C., Wong P.C. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol. Neurodegener. 2013, 8:18.
11. Lalloyer F., Pedersen T.A., Gross B., Lestavel S., Yous S., Vallez E., Gustafsson J.A., Mandrup S., Fievet C., Staels B., Tailleux A. Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1488-1495.
12. Minkeviciene R., Rheims S., Dobszay M.B., Zilberter M., Hartikainen J., Fulop L., Penke B., Zilberter Y., Harkany T., Pitkanen A., Tanila H. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J.Neurosci. 2009, 29:3453-3462.
13. Mucke L., Selkoe D.J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2012, 2:a006338.
14. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818.
15. Price A.R., Xu G., Siemienski Z.B., Smithson L.A., Borchelt D.R., Golde T.E., Felsenstein K.M. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340:924.d.
16. Roberson E.D., Halabisky B., Yoo J.W., Yao J., Chin J., Yan F., Wu T., Hamto P., Devidze N., Yu G.Q., Palop J.J., Noebels J.L., Mucke L. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J.Neurosci. 2011, 31:700-711.
17. Simeone T.A., Simeone K.A., Samson K.K., Kim do Y., Rho J.M. Loss of the Kv1.1 potassium channel promotes pathologic sharp waves and high frequency oscillations in invitro hippocampal slices. Neurobiol. Dis. 2013, 54:68-81.
18. Smart S.L., Lopantsev V., Zhang C.L., Robbins C.A., Wang H., Chiu S.Y., Schwartzkroin P.A., Messing A., Tempel B.L. Deletion of the K(V)1.1 potassium channel causes epilepsy in mice. Neuron 1998, 20:809-819.
19. Tesseur I., Lo A.C., Roberfroid A., Dietvorst S., Van Broeck B., Borgers M., Gijsen H., Moechars D., Mercken M., Kemp J., D'Hooge R., De Strooper B. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340:924.e.
20. Ulrich J.D., Burchett J.M., Restivo J.L., Schuler D.R., Verghese P.B., Mahan T.E., Landreth G.E., Castellano J.M., Jiang H., Cirrito J.R., Holtzman D.M. Invivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol. Neurodegener. 2013, 8:13.
21. Veeraraghavalu K., Zhang C., Miller S., Hefendehl J.K., Rajapaksha T.W., Ulrich J., Jucker M., Holtzman D.M., Tanzi R.E., Vassar R., Sisodia S.S. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340:924-f.
22. Verret L., Mann E.O., Hang G.B., Barth A.M., Cobos I., Ho K., Devidze N., Masliah E., Kreitzer A.C., Mody I., Mucke L., Palop J.J. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 2012, 149:708-721.